Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3901 - Prognostic significance of immunohistochemical subtyping and PAM50 intrinsic subtypes in male breast cancer (MaBC)

Date

10 Oct 2016

Session

Poster display

Presenters

Martina Alvarez

Citation

Annals of Oncology (2016) 27 (6): 68-99. 10.1093/annonc/mdw365

Authors

M. Alvarez1, A. Sanchez-Muñoz2, A. Santonja2, Y. Plata Fernández3, J. Miramón4, I. Zarcos Pedrinaci5, C. Llacer6, V. de Luque7, M.J. Lozano León8, J.M. Jerez8, L. Pérez Villa8, R. Lavado2, C. Ramirez9, A. Jiménez10, I. Rodrigo6, E. García11, L. Vicioso8, E. Alba Conejo2

Author affiliations

  • 1 Pathology, Biomedical Research Institute of Málaga (IBIMA), 29071 - Malaga/ES
  • 2 Medical Oncology, Biomedical Research Institute of Málaga (IBIMA), Malaga/ES
  • 3 Oncology, Complejo Hospitalario de Jaen Universidad de Jaen, 23007 - Jaen/ES
  • 4 Medical Oncology, Hospital de la Serrania, Ronda (Málaga)/ES
  • 5 Oncology, A.S Hospital Costa del Sol, 29603 - Malaga/ES
  • 6 Servicio De Oncología Médica, Hospital Regional Universitario Carlos Haya, Malaga/ES
  • 7 Medical Oncology, iomedical Research Institute of Malaga (IBIMA)-Hospital Universitario Regional y Virgen de la Victoria, Malaga, Malaga/ES
  • 8 Pathology, Biomedical Research Institute of Málaga (IBIMA), Malaga/ES
  • 9 Pathology Department, Complejo Hospitalario de Jaen Universidad de Jaen, Jaen/ES
  • 10 Pathology Department, Hospital Regional Universitario Carlos Haya, Malaga/ES
  • 11 Pathology Department, Hospital de la Serrania, Ronda (Málaga)/ES
More

Resources

Abstract 3901

Background

Substantial controversy exists about the prognostic role of molecular tumor subtypes in MaBC. It is mainly classified as a luminal disease, but survival differences between Luminal A and B are not clarified. The aim of this study was to assess the molecular subtype profiles of MaBC, and subsequently the clinical outcome, using two different approaches: mmunochemistry and the gene-expression profile PAM50.

Methods

A total of 69 cases of invasive MaBC, were examined using an immunohistochemical standard staining for estrogen receptor (ER), progesterone receptor (PR), androgen receptor (AR), human epidermal growth factor receptor 2 (HER2), cytokeratin 5/6 (CK5/6), epidermal growth factor receptor (EGFR) and Ki-67. Immunohistochemical subtypes were classified according to Cheang et al. (2009). Gene-expression profiling was performed on a research-use-only (RUO) nCounter Analysis System using the RUO PAM50 assay analyzed with the Prosigna® algorithm. The Kaplan-Meier method was used to estimate Overall Survival (OS).

Results

Patients had a median age of 63 (range 23-92). The mean and median OS were 184 and 156 months, respectively. At diagnosis, patients were mainly stage I (27.5%) and II (40.6%). When subtyping by IHQ and PAM50, the majority of samples were luminal B (49.3% and 59.7%, respectively) followed by luminal A (44.3% and 29.9%). Only 5.8% by IHQ and 10.4% by PAM50 were non-luminal (1 basal-like, 2 non-basal triple negative and 1 Her2-enriched by IHQ and 7 Her2-enriched by PAM50). We found a strong association between both IHQ and PAM50 classifications (p-value = 0.007). There were no significant differences in OS between luminal A and luminal B subtypes, neither by immunohistochemistry (p = 0.22) nor in PAM50 subtypes (p = 0.89). However, Her2-enriched patients by PAM50 showed significant worse prognosis (p = 0.009).

Conclusions

The most common subtypes in our MaBC cohort were luminal B followed by luminal A. No differences were found between these tumor subtypes in terms of patient outcome. However, Her2-enriched patients by PAM50 showed worse prognosis. Further research with larger cohorts is needed to unveil the real role of the different subtypes in MaBC.

Clinical trial identification

Legal entity responsible for the study

Biomedical Research Institute of Malaga (IBIMA)-Hospital Universitario Regional y Virgen de la Victoria, Malaga (Spain)

Funding

FIMABIS

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings